Recruiting

Observational StudyIntegrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Sponsor:

International Extranodal Lymphoma Study Group (IELSG)

Code:

NCT05700149

Conditions

Nodal Marginal Zone Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Conditions

Nodal Marginal Zone Lymphoma

Study ID

NCT05700149

Start date

Apr 11, 2024

Status verified date

Jun, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or female adults 18 years or older
2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000
3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve
4. Availability of the baseline and follow-up annotations

Exclusion Criteria:

1\. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

Define and quantify molecular subsets. [ Time Frame: Two years: from the end of samples collection to the end of study analysis ]

Central Contacts and Locations

Central contacts

IELSG - Study Coordination Office

+41586667321 ielsg@ior.usi.ch

Davide Rossi, MD

+41918118540 davide.rossi@eoc.ch

Locations

University of Miami

Recruiting

Miami, Florida, United States, 33136

Principal Investigator:

Jennifer Chapman, MD

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Principal Investigator:

Rebecca King, MD

Weill Cornell Medical

Recruiting

New York, New York, United States, 10065

Principal Investigator:

Giorgio Inghirami, MD

Ohio Health Riverside Methodist Hospital

Recruiting

Columbus, Ohio, United States, 43214

Principal Investigator:

William Basem

Princess Margaret Cancer Centre

Recruiting

Toronto, Canada

Principal Investigator:

John Kuruvilla, MD

More Information

Sponsor

International Extranodal Lymphoma Study Group (IELSG)

Last update posted

Jun 22, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by International Extranodal Lymphoma Study Group (IELSG) on 2026-06-22.